Dmitry Balyasny’s LENZ Therapeutics LENZ Stock Holding History

Dmitry Balyasny’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,747	Closed	-$591K	–	2502
2021 Q2	$591K	Buy	+2,747	New	+$478K	﹤0.01%	1494

Other funds holding LENZ

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dmitry Balyasny's LENZ Position: Q3 2021 in Review

Dmitry Balyasny sold out of LENZ Therapeutics (LENZ) in Q3 2021, closing a stake of 2,747 shares — an estimated $591K sold.

Dmitry Balyasny first reported a position in LENZ in Q2 2021 and held it in 1 quarter. The position peaked at $591K in Q2 2021. 60 funds tracked by Wall St. Rank hold LENZ as of Q3 2021.

Dmitry Balyasny reported no remaining LENZ Therapeutics position as of Q3 2021 after selling out during the quarter.
Dmitry Balyasny sold 2,747 LENZ Therapeutics shares in Q3 2021, an estimated $591K.
Dmitry Balyasny first reported a position in LENZ Therapeutics in Q2 2021 and held it in 1 quarter.
Dmitry Balyasny's LENZ Therapeutics position peaked at $591K in Q2 2021.
60 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2021.

Based on Balyasny Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.